Grunenthal Presents a New Website for the Topical Treatment of Postherpetic Neuralgia (PHN)

Grunenthal GmbH

Grunenthal Presents a New Website for the Topical Treatment of Postherpetic Neuralgia (PHN)

AsiaNet 53113

AACHEN, Germany, May 22 /PRN=KYODO JBN/ --

     Healthcare professionals who would like to know more about the topical

treatment of postherpetic neuralgia (PHN) can now find useful information

online. PHN is a chronic disabling pain condition with symptoms often described

as burning, stabbing, or shooting pain, and caused by a previous herpes zoster

infection (commonly known as shingles). The new website answers questions like

"Why is PHN often misdiagnosed?" "Which questions help making the correct

diagnosis?" and "What are effective, well tolerated and easy-to-use first-line

treatment options?" Please visit http://www.versatis.com for details.

    About Gruenenthal

    The Gruenenthal Group is an independent, family-owned, international

research-based pharmaceutical company headquartered in Aachen, Germany.

Building on its unique position in pain treatment, its objective is to become

the most patient-centric company and thus to be a leader in therapy innovation.

Gruenenthal is one of the last remaining five research-oriented pharmaceutical

companies with headquarters in Germany which sustainably invests in research

and development. The research and development costs amounted to a preliminary

of about 26 percent of revenues in 2012. Gruenenthal's research and development

strategy concentrates on selected fields of therapy and state-of-the-art

technologies. We are intensely focused on discovering new ways to treat pain

better and more effectively, with fewer side-effects than current therapies.

Altogether, the Gruenenthal Group has affiliates in 26 countries worldwide.

Gruenenthal products are sold in more than 155 countries and today approx.

4,400 employees are working for the Gruenenthal Group worldwide. In 2012,

Gruenenthal achieved revenues of EUR 973 mn. More information:

http://www.grunenthal.com.

    Embargo: This information is intended for healthcare professionals only.

    Contact: Jeanette Huebsch, Senior Manager Versatis, Gruenenthal Europe &

Australia

    Phone: +49-241-569-1487, email: jeanette.huebsch@grunenthal.com

SOURCE: Grunenthal GmbH

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中